Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2002-06-14
2004-02-17
Henley, III, Raymond (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S002600, C514S011400, C514S012200, C514S021800, C514S056000, C514S563000
Reexamination Certificate
active
06693073
ABSTRACT:
FIELD OF THE INVENTION
The present invention relates to pulmonary delivery of active agents. Acylated or sulfonated amino acids are used as carriers to facilitate pulmonary delivery of active agents to a target.
BACKGROUND OF THE INVENTION
Conventional means for delivering active agents are often severely limited by biological, chemical, and physical barriers. Typically, these barriers are imposed by the environment through which delivery occurs, the environment of the target for delivery, or the target itself. Biologically or chemically active agents are particularly vulnerable to such barriers.
For example, in the delivery to animals of biologically active or chemically active pharmacological and therapeutic agents, barriers are imposed by the body. Examples of physical barriers are the skin and various organ membranes that must be traversed before reaching a target. Chemical barriers include, but are not limited to, pH variations, lipid bi-layers, and degrading enzymes.
Pulmonary delivery to the circulatory system for many biologically active agents could be the route of choice for administration to animals because delivery to the blood is much more rapid than with other routes of delivery. In addition, delivery to the lung itself may be desired, e.g., for treatment of ailments of the pulmonary system. However, pulmonary delivery may not be practical because of physical barriers such as lipid bi-layers, and membranes that are relatively impermeable to certain biologically active agents, but which must be traversed before an agent can reach the circulatory system. In other cases, pulmonary delivery may be achieved, but not efficiently enough for practical purposes.
There is presently a need for simple, inexpensive pulmonary delivery systems which are easily prepared and which can deliver a broad range of active agents in an efficient manner.
REFERENCES:
patent: 6440929 (2002-08-01), Milstein et al.
patent: 4446 (1966-11-01), None
patent: 48-37819 (1973-11-01), None
patent: WO 95/11690 (1995-05-01), None
patent: WO 96/12473 (1996-05-01), None
patent: WO 99/29705 (1999-06-01), None
Palagiano, F. et al.: “Synthesis, stability and anticonvulsant activity of two new GABA prodrugs,”Pharamazic, 52 (4): 272-276 (1997), XP-001084051.
Yalcin, I. et al.: “Synthesis and Microbiological Activity of Some Novel N-(2-Hydroxyl-5-Substitutedphenyl)Benzacetamides, Phenoxyacetamides and Thiophenoxycetamides as the Possible Metabolites of Antimicrobial Active Benzoxazoles,”IL Farmaco, 52 (11), 685-689 (1997).
Nov. 19, 2002 European Search Report Issued in EP Application No. 99938806.
Flanders Elizabeth
Gschneidner David
Leipold Monica
Leone-Bay Andrea
Milstein Sam J.
Darby & Darby
Emisphere Technologies Inc.
Henley III Raymond
LandOfFree
Pulmonary delivery of active agents does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pulmonary delivery of active agents, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pulmonary delivery of active agents will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3311114